Clinical Trials Logo

Cervical Cancer clinical trials

View clinical trials related to Cervical Cancer.

Filter by:

NCT ID: NCT05996796 Completed - Cervical Cancer Clinical Trials

Dry Run of the ScreenUrSelf Trial

Start date: April 10, 2023
Phase: N/A
Study type: Interventional

The proposed study is the Dry Run preceding the ScreenUrSelf trial.

NCT ID: NCT05990803 Recruiting - Cervical Cancer Clinical Trials

A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Cervical Cancer and Other Gynecological Malignancies

Start date: November 6, 2023
Phase: Phase 2
Study type: Interventional

Objective: To explore the efficacy, safety and tolerability of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in patients with recurrent or metastatic cervical cancer and other gynecological malignancies, and to further explore the optimal dose and mode of combination.

NCT ID: NCT05979610 Recruiting - Cervical Cancer Clinical Trials

Using Reiki Therapy to Improve Symptoms Associated With Brachytherapy in Patients With Gynecological Malignancies

Reiki-Brachy
Start date: October 9, 2023
Phase: Phase 2
Study type: Interventional

The goal of this open label, randomized, controlled clinical trial is to assess the benefits of providing Reiki therapy to subjects receiving their first brachytherapy treatment for gynecological malignancies. Participants will either receive a session of Reiki therapy or usual care during the standard wait time between the placement of the brachytherapy device and brachytherapy treatment. Questionnaires will be administered at various time points on the day of the participant's first brachytherapy treatment as well as at the three month follow-up time point. Researchers will compare the intervention (Reiki therapy) and control (usual care) groups to assess the impact of the Reiki therapy on anxiety, pain, state anxiety, depression, and physiological measurements.

NCT ID: NCT05975593 Recruiting - Pancreatic Cancer Clinical Trials

MicroEnvironment Tumor Effects of Radiotherapy - Comprehensive Radiobiology Assessment TRial

METEOR-CRATR
Start date: December 19, 2023
Phase:
Study type: Observational

This study is a dynamically adjustable prospective longitudinal study designed to capture biospecimen (biopsy, blood, surgical) and multimodal treatment (imaging, dosimetry, clinical) data before, during, and after treatment with definitive-intent standard of care (SOC) radiotherapy for patients with locally advanced cervical and pancreatic cancer.

NCT ID: NCT05973487 Recruiting - Ovarian Cancer Clinical Trials

A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors

Start date: May 6, 2024
Phase: Phase 1
Study type: Interventional

TScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous participant-derived T cells are engineered to express a T cell receptor that recognizes cancer-associated antigens presented on specific Human Leukocyte Antigen (HLA) molecules. This is a multi-center, non-randomized, multi-arm, open-label, basket study evaluating the safety and preliminary efficacy of single and repeat dose regimens of TCR'Ts as monotherapies and as T-Plex combinations after lymphodepleting chemotherapy in participants with locally advanced, metastatic solid tumors disease.

NCT ID: NCT05959564 Completed - Cervical Cancer Clinical Trials

A Chatbot Intervention for Reducing HPV Vaccine Hesitancy

Start date: July 26, 2023
Phase: N/A
Study type: Interventional

The goal of this project is to test the efficacy of a chatbot intervention for reducing HPV vaccine hesitancy among African American parents. An online experiment will be conducted to test the effectiveness of the chatbot intervention with African American parents. Results of this project will inform future communication interventions for reducing vaccine hesitancy among African American parents.

NCT ID: NCT05955105 Recruiting - Ovarian Cancer Clinical Trials

A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies

Start date: July 25, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a multicenter, open-label, phase Ib/IIa study. The first part of the study will evaluate the safety, tolerability and preliminary efficacy of ILB2109 and Toripalimab in patients with locally advanced or metastatic solid malignancies. The second part of the study will evaluate the efficacy of ILB2109 and Toripalimab in patients with selected advanced solid malignancies.

NCT ID: NCT05952947 Recruiting - Cervical Cancer Clinical Trials

HRYZ-T101 Injection for HPV18 Positive Solid Tumor

Start date: November 1, 2023
Phase: Phase 1
Study type: Interventional

A multicenter, open label, single arm dose escalation phase I study to evaluate the safety, tolerability, and efficacy of HRYZ-T101 injection for HPV18 positive solid tumor. The study will investigate RP2D of HRYZ-T101 TCR-T cell injection.

NCT ID: NCT05952141 Recruiting - Cervical Cancer Clinical Trials

Strategies to Close the Gap From CC Diagnosis to Treatment in Botswana

Start date: September 18, 2023
Phase: N/A
Study type: Interventional

Investigators will test the effectiveness of adaptive strategies on timely adoption of cervical cancer treatment in Botswana using a pragmatic trial design.

NCT ID: NCT05947513 Not yet recruiting - Cervical Cancer Clinical Trials

Concomitant Curcumin Palliative Radiotherapy in Advanced Cervical Cancer Trial

CuPRAC
Start date: October 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this clinical trial is to test curcumin as an adjunct treatment in patients with cervical cancer receiving standard-of-care palliative radiation. The main questions it aims to answer are: - Is adding curcumin to standard-of-care palliative radiotherapy of cervical cancer patients safe? - Does adding curcumin to standard-of-care palliative radiotherapy of cervical cancer patients improve therapeutic responses? - How much curcumin is absorbed into the body and how long will it stay in the body? Participants will: - Take two 500 mg curcumin capsules twice per day for 4-6 weeks in addition to the prescribed palliative radiotherapy. - Provide blood and urine samples for laboratory tests. - Provide blood samples to measure curcumin levels in their body. - Obtain CT-scan to measure their tumor response. - Complete questioners to measure improvements to their quality of life, if any.